Participated · Series C · Jan 2025

Truveta aggregates de-identified EHR data from a coalition of health systems into Truveta Data, a daily-updated, regulatory-grade dataset representing over 120 million patients. Launched in 2020, the company is a collaboration of some 30 health systems aligned on a mission to save lives with data. Its platform includes the Truveta Language Model, a large-language, multimodal AI model run on Microsoft Azure to normalize and transform billions of data points. Truveta is expanding into genotypic data through the Truveta Genome Project to link exomes and future multi-omics sequencing to clinical records. The combined genotypic and phenotypic database is intended for biopharma and academic research to accelerate drug discovery, optimize clinical trials, and train AI models. Data privacy and de-identification, along with Azure as the exclusive cloud provider for the genome project, are core operational elements described in the articles. Truveta collects privacy-safe, de-identified medical data from partner health systems and aggregates it for researchers. It partners with around 20 medical providers and ingests regular data from 42 states, aiming to build a living medical portrait of America. The company provides a software service that lets public-health researchers filter populations and drop into a Jupyter Notebook to build dashboards with data that updates daily. CEO Terry Myerson, formerly of Microsoft, says Truveta has its sights on 16% of all clinical care in the United States. Truveta has shared COVID-19 analyses from its platform, including findings that adverse events occur in fewer than 1% of fully vaccinated people and that Moderna patients showed 40% more events than Pfizer in their dataset. The company is not a nonprofit (it pays taxes), maintains an anti-advertising stance licensed for ethical medical research, and recently raised $100 million, bringing its capital base to around $200 million. Truveta operates a provider-led platform that brings together daily de-identified clinical data from its member health systems to deliver insights to clinicians and researchers. The platform aggregates tens of millions of patients and thousands of care facilities across 40 states and represents more than 15% of U.S. patient care. Truveta aims to help researchers find cures faster, empower clinicians with better data, and improve treatment and outcomes for diverse populations. The company emphasizes statistical representation across geography, race, ethnicity and other socioeconomic dimensions to address health disparities. Governance and investment come from its health system members, and earnings health providers receive from Truveta are intended to be reinvested into their communities. Truveta plans to hire technologists and health-data experts and invest in infrastructure and cloud-computing resources to build and scale the platform.

Led · Equity · Sep 2024

Sonoma Biotherapeutics is a clinical-stage biotech focused on engineered regulatory T cell (Treg) therapies to restore immune balance in serious autoimmune and inflammatory diseases. The company employs proprietary platform technologies and approaches to develop a new generation of targeted and durable gene-modified Treg cell therapies. Led by CEO Jeff Bluestone, Sonoma Bio operates out of San Francisco, CA and Seattle, WA. In March 2023 the company entered a collaboration and license agreement with Regeneron to research, develop and commercialize Treg therapies for inflammatory bowel disease and two other undisclosed indications, with a Regeneron option for a fifth indication. The collaboration integrates Regeneron’s VelociSuite technologies for discovery and characterization of fully human antibodies and T cell receptors with Sonoma Bio’s development and manufacturing approach. Sonoma plans to use the newly received funds to expand operations and its R&D sector. Sonoma Biotherapeutics pioneers adoptive regulatory T cell (Treg) therapies and a complementary Teff conditioning biologic to promote immune tolerance in autoimmune and inflammatory diseases. Its platform uses genome editing and target‑specific cell therapy to develop disease‑modifying, potentially curative medicines. The company’s two most advanced programs are SBT-77-7101, a CAR‑based Treg therapy for refractory rheumatoid arthritis, and SBT-11-5301, a Teff conditioning biologic being investigated as monotherapy for Type 1 diabetes and as a conditioning agent to enhance Treg efficacy. Sonoma plans to advance these programs into the clinic and to continue discovery work on additional Treg programs. Proceeds from the recent financing will also be used to scale manufacturing capacity to support initial clinical studies. The company was founded by leaders in Treg biology and cell therapy and combines genetic engineering, development, and manufacturing capabilities to translate its approach into clinical trials. Sonoma Biotherapeutics is developing adoptive regulatory T-cell (Treg) therapies using next-generation genome editing and target-specific cell therapy to treat autoimmune and degenerative diseases. The company aims to move cell therapy beyond cancer into indications including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, ALS and Alzheimer’s. Sonoma recently expanded its Series A to $70 million to advance its pipeline and platform capabilities. The financing and new hires are intended to support research, development and manufacturing of next-generation Treg therapeutics. Leadership additions include a new chief medical officer and vice presidents for portfolio/program/alliance management and discovery. Sonoma is based in South San Francisco and Seattle and was founded by pioneers in Treg biology and cell therapy. Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies aimed at restoring self-tolerance and halting harmful inflammatory responses in autoimmune and degenerative diseases. Its programs target conditions including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, ALS and Alzheimer’s. The company combines research, development and manufacturing capabilities in cell therapy and genetic engineering to advance Treg candidates from target identification through preclinical and clinical development. Sonoma emphasizes engineering Tregs to target disease-causing antigens to reduce systemic effects and improve tissue-specific control of inflammation. The team includes founder and CEO Jeffrey Bluestone, PhD, and three other founding Treg field scientists, as well as executives and board members with deep cell therapy experience. Sonoma operates out of South San Francisco, CA and Seattle, WA.

Participated · Series B · May 2022

Vyriad engineers viruses, viral vectors, and envelope glycoproteins to deliver therapeutic genes directly to selected cells, eliminating the need for complex ex vivo manufacturing. Its proprietary lentiviral platform employs engineered G proteins to create highly specific, blood-stable vectors that can reprogram immune cells in the body, enabling scalable access to CAR-T therapies. Lead candidate VV169 combines an optimized lentiviral vector (LV-169) with a BCMA-directed CAR transgene and is slated to enter first-in-human Phase 1 testing in relapsed or refractory multiple myeloma patients. Preclinical data presented at ASH 2025 showed VV169 eliminated disseminated multiple myeloma in all tested humanized mouse models, even at the lowest dose. Future plans include advancing VV169 into the clinic in 2026 and validating the broader delivery platform for additional in vivo CAR-T programs. Vyriad also maintains corporate partnerships with Regeneron Pharmaceuticals and Novartis, supporting development across oncolytic virotherapy, in vivo gene therapy, and gene-editing applications. The company is privately held and headquartered in Rochester, Minnesota. To date, it has secured at least $85 million in Series B funding to fuel its ongoing clinical and platform development.

Participated · Equity · Jul 2021

ISA Pharmaceuticals, based in Oegstgeest, The Netherlands, is a clinical-stage immunotherapy company led by CEO Gerben Moolhuizen developing treatments using its Synthetic Long Peptide (SLP®) platform. Its lead asset, ISA101b, is in late-stage clinical trials for HPV16-induced cancers in collaboration with Regeneron. Other preclinical assets target chronic hepatitis B (HBV), PRAME-overexpressing cancers, cancers caused by other HPV types, and SARS-CoV-2. The company closed a €26M funding round. ISA intends to use the proceeds to advance ISA101b toward first marketing authorization and to broaden its clinical immunotherapy pipeline. The SLP® platform underpins its development strategy across oncology and infectious-disease indications.

Participated · Series G · Jun 2020

DNAnexus provides a cloud-based biomedical data analysis platform that enables researchers and life sciences companies to analyze genomic, transcriptomic, proteomic, metabolomic, and clinical datasets together. The company powers large-scale initiatives — it built and supports the UK Biobank Research Analysis Platform and exclusively partnered with the FDA to power precisionFDA. DNAnexus reports more than 12,000 platform users across 48 countries, stores over 65 petabytes of data, and says its stored data has grown 70% per year since 2015. Its customer base includes seven of the top 10 pharmaceutical companies and eight of the top 10 diagnostics companies. The company will use new funding to accelerate its product roadmap, advance its core genomics and multi-omics platform, expand internationally, and support integration of new AI and machine-learning technologies to drive precision medicine. DNAnexus offers an enterprise-grade, cloud-native informatics platform that simplifies complex data analysis, clinical data management, and insights at population scale. The DNAnexus Platform combines genomics, multi-omics, and real-world data with clinical datasets to support diagnostics, drug discovery, and cross-institutional collaboration. Customers run 10 million core processing hours per month and now store 28 petabytes of data, a dataset that has grown roughly 70% per year over the past four years. Its customer base spans government, biopharmaceutical, clinical diagnostics, healthcare, and academic research across 33 countries and includes eight of the top 10 clinical diagnostics companies and seven of the top 10 pharmaceutical companies. The platform supports some of the largest human genome sequencing projects and powers FDA’s precisionFDA platform. DNAnexus reports continued customer growth during the COVID-19 pandemic as organizations adopted its virtual cloud workspace. The company says the financing will advance its global expansion and further development of its data science and scaling capabilities. DNAnexus provides a secure, scalable platform for managing and analyzing genomics and other biomedical data. Its Apollo platform enables multi-omics and clinical data exploration, analysis, and discovery across the DNAnexus global network. The company operates in 33 countries, serving thousands of researchers across biopharmaceutical, bioagricultural, sequencing services, clinical diagnostics, government, and research consortia. DNAnexus supports major projects including NIH’s All of Us, St. Jude Cloud, AstraZeneca’s 2‑million genome initiative, and the Regeneron‑Geisinger collaboration. The firm offers cloud-based solutions for research, clinical diagnostics, and clinical trials and emphasizes cross-institutional collaboration on large biomedical datasets. The recent financing is positioned to support further development of translational research solutions and continued growth in genomics. DNAnexus provides a secure, scalable cloud platform that enables enterprises and research organizations to manage, analyze and share large genomic and biomedical datasets. The company offers products including the DNAnexus Platform and the recently launched Mosaic Microbiome Platform, and has an early access program for Google Brain’s DeepVariant technology. It is developing and preparing to deploy a Translational Informatics Suite aimed at pharmaceutical and research customers. DNAnexus serves thousands of researchers across biopharma, clinical diagnostics, sequencing services, government and research consortia, and operates globally across North America, Europe, Asia‑Pacific (including China), South America and Africa. The company has announced collaborations with AstraZeneca’s Centre for Genomics Research and Rady Children’s Institute for Genomic Medicine. Recent financing will support expansion in the clinical trials market and continued product development and deployment. DNAnexus provides an enterprise PaaS that centralizes management, analysis, and sharing of DNA sequence data for labs and large organizations. The platform supplies secure, compliant cloud infrastructure that supports unlimited scaling of computational and storage resources and meets HIPAA, CLIA, and international regulatory requirements. It serves as a hub for collaboration, tool sharing, and access to reference genotypic and phenotypic datasets. Through projects with Stanford University and Baylor College of Medicine, DNAnexus processed over 17,000 genomes and generated more than 500 terabytes of genomic data, making those datasets available for follow-on analysis. The company reports rapid customer adoption and plans to expand capacity to support growing commercial and academic lab usage. DNAnexus has closed a $15 million Series C to accelerate commercialization of its enterprise platform.